Clinical features of heart failure with mid-range and preserved ejection fraction in octogenarians: Results of a multicentre, observational study

Basit Öğe Kaydı
dc.authoridmert, kadir ugur/0000-0002-1331-5365
dc.authoridOZLEK, BULENT/0000-0001-5429-1323
dc.contributor.authorOzlek, Bulent
dc.contributor.authorOzlek, Eda
dc.contributor.authorTekinalp, Mehmet
dc.contributor.authorKahraman, Serkan
dc.contributor.authorAgus, Hicaz Zencirklran
dc.contributor.authorCelik, Oguzhan
dc.contributor.authorCil, Cem
dc.date.accessioned2025-01-21T16:36:36Z
dc.date.available2025-01-21T16:36:36Z
dc.date.issued2019
dc.departmentKırıkkale Üniversitesi
dc.description.abstractObjectives: To compare real-world characteristics and management of individuals aged 80 and older with heart failure (HF) and mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) derived from a large cohort of survey and to compare them with those younger than 80 from the same survey. Methods: This is an observational, multicentre and cross-sectional study conducted in Turkey (NCT03026114). Consecutive 1065 (mean age of 67.1 +/- 10.6 years) patients admitted to the cardiology outpatient units with HFmrEF and HFpEF were included. Results: Participants aged 80 and older (n = 123, 11.5%) were more likely to be female (66.7% vs 52.5%, P = 0.003), had a higher prevalence of atrial fibrillation (49.6% vs 34%, P = 0.001), and anaemia (46.3% vs 33.4%, P = 0.005) than those who were younger than 80. N-terminal pro B-type natriuretic peptide levels were higher in those aged 80 and older than in those younger than 80 (1037 vs 550 pg/ml, P < 0.001). The prescription rates of HF medications (including in ACE-Is/ARBs, beta-blockers, MRAs, digoxin, ivabradine and diuretics) were similar (P > 0.05) in both groups. Octogenarians did not significantly differ from younger patients in the prevalence of HFmrEF (24.4% vs 22.9%) and HFpEF (75.6% vs 77.1%). Coronary artery disease was associated with HFmrEF (P < 0.05), whereas atrial fibrillation was associated with HFpEF (P < 0.05) in octogenarians. Conclusions: This study revealed that nearly 12% of the individuals with HFmrEF and HFpEF in this real-world sample were aged 80 and older. Participants aged 80 and older are more likely to be female and have more comorbidities than those who were younger than 80. However, HF medication profiles were similar in both groups. This study also showed that associated factors with HFmrEF and HFpEF were differ in octogenarians.
dc.identifier.doi10.1111/ijcp.13341
dc.identifier.issn1368-5031
dc.identifier.issn1742-1241
dc.identifier.issue4
dc.identifier.pmid30865367
dc.identifier.urihttps://doi.org/10.1111/ijcp.13341
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24346
dc.identifier.volume73
dc.identifier.wosWOS:000472227200010
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofInternational Journal of Clinical Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.titleClinical features of heart failure with mid-range and preserved ejection fraction in octogenarians: Results of a multicentre, observational study
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu